Biopharmaceutical company Altimmune, Inc. (ALT) on Monday announced that the company will report results from a Phase 1 clinical trial of ALT-801 in overweight and obese subjects.
The company said it will discuss the results in a pre-market press release, conference call and webcast on September 28 at 8:30 a.m. ET.
Altimmune said it is focused on developing treatments for obesity and liver diseases.
ALT closed Monday's trading at $15.19, up $0.22 or 1.47%, on the NYSE. The stock further gained $0.60 or 3.95% in the after-hours trade.
For comments and feedback: editorial@rttnews.com